The sensitivity to 18 antimicrobial drugs was examined for 66 strains of Ureaplasma sp isolated from respiratory tracts of calves suffering from enzootic pneumonia, urinary tracts of bulls and eyes of cows suffering from infectious bovine kerato-conjunctivitis. Furamizole, tiamulin fumarate, erythromycin lactobionate, malidomycin C, doxycycline hydrochloride, kitasamycin tartrate, tylosin tartrate, T-2636C, tetracycline hydrochloride, oxytetracycline hydrochloride, chlortetracycline hydrochloride, oleandomycin phosphate, furazolidone, spiramycin adipate, chloramphenicol and thiophenicol showed strong inhibiting activity on all the test strains. Among them, furamizole, tiamulin fumarate and erythromycin lactobionate were most active. Kanamycin sulphate showed weak activity on all the strains tested. The differences in origin of the test strains did not affect their sensitivity to any of the drugs.

01 Jan 1978·National Institute of Animal Health quarterly

Sensitivites in vitro to antimicrobial drugs of bovine mycoplasmas isolated from respiratory and genital tracts.

Article

Author: Kishima, M ; Hashimoto, K ; Minato, H

A total of 155 Mycoplasma strains were examined for sensitivity to nine antibiotics and four nitrofurans by the agar dilution method. They consisted of 69 strains of Mycoplasma bovirhinis, 33 strains of M. bovigenitalium, 49 strains of Acholeplasma laidlawii and four strains of A. modicum isolated from the nasal secretions, tracheas and lungs of calves manifesting respiratory symptoms and from bovine genital tracts collected at a slaughterhouse. As a result, furamizole and mitomycin C showed the strongest growth-inhibiting effect on all the strains. They were followed in this effect by kitasamycin tartrate, spiramycin adipate, tylosin tartrate, tetracycline-HCl and chloramphenicol. Furthermore, these five drugs were followed in the effect by furazolidone, nitrofurantoin and sodium nifurstyrenate. Fradiomycin sulfate and kanamycin sulfate showed only little effect on all the strains. Erythromycin lactobionate showed a strong growth-inhibiting effect on the Acholeplasma strains, but not on the Mycoplasma strains. There were some cross resistant strains of the Acholeplasma species to the effects of the macrolides.

01 Jan 1974·The Journal of AntibioticsQ4 · MEDICINE

in vitro ACTIVITY OF KITASAMYCIN AGAINST GRAM-POSITIVE COCCI

Q4 · MEDICINE

Article

Author: Gerald P. Bodey ; Yvonne Balducci

All Streptococcus pyogenes and Diplococcus pneumoniae strains tested in vitro were inhibited by 0.39 and 1.56 μg kitasamycin tartrate [37280-56-1]/ml, resp.; 98% of penicillin G sensitive and 99% of penicillin G resistant Staphylococcus aureus strains were inhibited by the higher concentrationMinocycline [10118-90-8], cephalothin [153-61-7], erythromycin [114-07-8], clindamycin [18323-44-9], and dicloxacillin [3116-76-5] were as active or more active than kitasamycin against gram-pos. cocci.

100 Deals associated with Kitasamycin Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02000	-	-	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acne Vulgaris	China	-	01 Jan 1984
Diphtheria	China	-	01 Jan 1984
Gonorrhea	China	-	01 Jan 1984
Gram-Positive Bacterial Infections	China	-	01 Jan 1984
Legionnaires' Disease	China	-	01 Jan 1984
Respiratory Tract Infections	China	-	01 Jan 1984
Scarlet Fever	China	-	01 Jan 1984
Streptococcal Infections	China	-	01 Jan 1984
Whooping Cough	China	-	01 Jan 1984

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Kitasamycin Tartrate

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation